英国与荷兰动脉粥样硬化性心血管疾病患者低剂量利伐沙班处方趋势
该研究基于英国CPRD Aurum和荷兰PHARMO数据库,分析2015-2022年ASCVD患者低剂量利伐沙班(2.5 mg每日两次)新使用率。指南更新后英国发生率从12.4升至124.0/10万人年(IRR 10.0),荷兰从2.4升至16.3(IRR 6.7),但整体仍未广泛进入临床实践。
要点
- 指南更新后两国低剂量利伐沙班新使用率均显著上升,英国IRR 10.0,荷兰IRR 6.7。
- 使用者较非使用者更年轻(英国平均差-6.1岁,荷兰-2.4岁)且男性比例更高(英国差11.5%,荷兰差13.4%)。
- 尽管增长显著,低剂量利伐沙班在ASCVD患者中仍未广泛普及。
核心结论
- 指南更新后英国和荷兰ASCVD患者低剂量利伐沙班使用率均出现统计学显著增长。
- 两国之间存在国际差异,且低剂量利伐沙班尚未广泛进入临床实践。
研究设计与样本
- 横断面中断时间序列分析,使用英国CPRD Aurum和荷兰PHARMO数据库2015年1月1日至2022年2月28日数据。
- 英国纳入721 271名符合条件的ASCVD受试者,荷兰纳入394 851名。
- 计算新使用(182天内)的发生率(IR)和与2015-2018参考期比较的发生率比(IRR)。
主要发现
- 英国2015-2018年新使用IR为12.4/10万人年,2020-2022年为124.0(IRR 10.0,95%CI 8.5-11.8)。
- 荷兰2015-2018年IR为2.4/10万人年,2020年为16.3(IRR 6.7,95%CI 4.0-11.4)。
- 使用者较非使用者更年轻(英国平均差-6.1岁,荷兰-2.4岁;P<.05),男性比例更高(英国差11.5%,荷兰差13.4%;P<.001)。
临床怎么用
- 临床药学智能体应关注ASCVD患者低剂量利伐沙班(2.5 mg每日两次)的适应证评估与处方趋势。
- 用药前需综合评估患者年龄、性别及合并症特征,识别可能的使用者人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Low-dose rivaroxaban has been indicated for the management of atherosclerotic cardiovascular disease (ASCVD) after recent (2019-2020) updates to European guidelines. We aimed to describe prescription trends of low-dose rivaroxaban in ASCVD patients over the period 2015-2022 in two European countries, to compare the trends before and after guideline changes, and to determine the characteristics of users. METHODS: In a cross-sectional interrupted time series analysis, utilization of low-dose rivaroxaban (2.5 mg, twice daily) was measured in Clinical Practice Research Datalink Aurum (United Kingdom [UK]) and the PHARMO Database Network (the Netherlands) from 1 January 2015 to 28 February 2022 in patients with an ASCVD diagnosis. Incidence rates (IRs) and incidence rate ratios (IRRs) of new use (within 182 days) compared to the reference period, 2015-2018, were calculated. Age, sex and comorbidities of users were compared to those of nonusers. RESULTS: In the UK, from 721 271 eligible subjects the IR of new use of low-dose rivaroxaban in the period 2015-2018, before guideline changes, was 12.4 per 100 000 person-years and after guideline changes in 2020-2022 was 124.0 (IRR 10.0, 95% confidence interval [CI] 8.5, 11.8). In the Netherlands from 394 851 subjects, the IR in 2015-2018 was 2.4 per 100 000 person-years and in 2020 was 16.3 (IRR 6.7, 95% CI 4.0, 11.4). Users were younger (UK mean difference [MD] -6.1 years, Netherlands -2.4 years; P < .05) and more likely to be male (UK difference 11.5%, Netherlands 13.4%; P < .001) than nonusers. CONCLUSIONS: There was a statistically significant increase in the use of low-dose rivaroxaban for the management of ASCVD after guideline changes in the UK and the Netherlands. There were international differences, but low-dose rivaroxaban has not been put into widespread practice.
引用
- Hunt NB, Pajouheshnia R, Salih A, et al. Prescribing of low-dose rivaroxaban in patients with atherosclerotic cardiovascular disease in the United Kingdom and the Netherlands. Br J Clin Pharmacol. 2023. PMID: 36890111. doi:10.1111/bcp.15708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。